Tips en venn



Send tips til:
(Bruk komma mellom flere adresser)

Din e-post adresse:

Din kommentar:

Tips en venn om denne portalen »
Om oss » Retningslinjer » Kontakt redaksjonen »
TIPS en venn »

Børs > Swiss

Annonse:
Van Lanschot Kempen neemt de wealth managementactiviteiten van UBS in Nederland over.

Van Lanschot Kempen en UBS maken vandaag bekend dat zij overeenstemming hebben bereikt over de overname door Van Lanschot Kempen van de wealth managementactiviteiten van UBS in Nederland.

(inpublic.globenewswire.com)
[07.06.2017 09:26]

Les mer »
Van Lanschot Kempen acquires UBS's domestic wealth management activities in the Netherlands.

Van Lanschot Kempen and UBS today announced that they have reached agreement on the acquisition by Van Lanschot Kempen of UBS's domestic wealth management activities in the Netherlands.

(inpublic.globenewswire.com)
[07.06.2017 09:26]

Les mer »
Annonse:
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval.

Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Use in its Dialysis Facilities and Invests $50 Million in Akebia at a Premium -- -- Additional Funds Support Vadadustat Global Development Program to Data - -.

(inpublic.globenewswire.com)
[16.05.2017 07:45]

Les mer »
OP Ryhmän osavuosikatsaus 1.1.-31.3.2017: Talous kunnossa, uudistuminen jatkuu.

OP Ryhmän osavuosikatsaus 1.1.-31.3.2017: Talous kunnossa, uudistuminen jatkuu.

(inpublic.globenewswire.com)
[27.04.2017 12:04]

Les mer »
GAM Holding AG: Interim management statement for the three-month period to 31 March 2017.

Assets under management of CHF 69.9 billion, up 2% from 31 December 2016, driven by positive investment performance, partly offset by negative foreign exchange movements.

(inpublic.globenewswire.com)
[18.04.2017 08:41]

Les mer »
GAM Holding AG: Wahlabsicht an der Generalversammlung von Silchester International Investors LLP.

Die Aktien von GAM mit Sitz in Zürich sind an der SIX Swiss Exchange notiert und Teil des Swiss Market Index Mid. Die Gruppe verwaltet per 31. Dezember 2016 Vermögen von CHF 120.7 Milliarden .

(inpublic.globenewswire.com)
[13.04.2017 19:16]

Les mer »
Actelion erhält Marktzulassung der Europäischen Kommission für Ledaga zur Behandlung von MF-CTCL.

Actelion Ltd gab heute bekannt, dass die Europäische Kommission die Marktzulassung für den Einsatz von 160 Mikrogramm/g Ledaga.

(inpublic.globenewswire.com)
[07.03.2017 12:26]

Les mer »
Actelion is granted marketing authorization by the European Commission for Ledaga for the treatment of MF-CTCL.

Actelion Ltd announced today that the European Commission has granted marketing authorization for the use of Ledaga.

(inpublic.globenewswire.com)
[07.03.2017 12:24]

Les mer »
10/02-2017 17:35:24: Actelion concludes second line share repurchase program.

Actelion Pharmaceuticals Ltd / Actelion concludes second line share repurchase program . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

(Netfonds)
[10.02.2017 17:37]

Les mer »
HMM Cuts Net Loss, Expects Losses until Mid-2018 zoom.

South Korea’s container carrier Hyundai Merchant Marine has managed to narrow its net loss in 2016, mainly due to a number of asset sales undertaken during the year.

(World Maritime News)
[10.02.2017 11:18]

Les mer »
Today on 2 Feb.

2017 at 3 pm, OP Financial Group received information on the ECB's decision on raising the risk weights for certain OP Financial Group's asset classes for a fixed period.

(inpublic.globenewswire.com)
[02.02.2017 21:56]

Les mer »
JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY.

Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion Share as Stock Dividend.

(inpublic.globenewswire.com)
[26.01.2017 07:38]

Les mer »
Viddi.no™ - best på lokale søk.
|Om Viddi.no | Kontakt oss på support (a) viddi.no | Copyright® - 2006 Viddinews AS |